Microbot Medical
Massachusetts medtech company behind LIBERTY, a single use, remotely operated endovascular robot.
Microbot Medical develops the LIBERTY Endovascular Robotic System, a fully disposable robot that lets physicians run peripheral endovascular procedures remotely. The company is listed on Nasdaq as MBOT and is based in Hingham, Massachusetts. In January 2025 it closed a registered direct offering of 3,788,550 shares at $2.27 together with a concurrent private placement of preferred investment options, raising about $8.6 million gross. A month later it closed a second registered direct offering of 6,103,289 shares at $2.13 that brought in about $13 million gross, with H.C. Wainwright acting as placement agent on both deals. In September 2025 LIBERTY received FDA 510(k) clearance for peripheral endovascular use, which the company described as the first such clearance for a single use, remotely operated system. Its pivotal study reported full navigation success with no device related adverse events and a 92% relative cut in physician radiation exposure.
- Latest funding
- $13M
- Total funding
- $21.6M
- Latest valuation
- —
- Founded
- —
- Country
- United States
- Feb 11, 2025Registered direct offering$13M
- Jan 10, 2025Registered direct offering and concurrent private placement$8.6M